Bispecific Antibodies
•60 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (60)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
The company markets bispecific antibodies (TECVAYLI, TALVEY), a distinct antibody modality.
|
$491.06B |
$204.65
+0.37%
|
|
ABBV
AbbVie Inc.
AbbVie is pursuing bispecific antibodies (e.g., ABBV-383), a distinct oncology modality.
|
$417.40B |
$230.44
-2.47%
|
|
AZN
AstraZeneca PLC
IO bispecific antibodies are a key immuno-oncology modality in AZN's pipeline.
|
$282.10B |
$91.75
+0.82%
|
|
MRK
Merck & Co., Inc.
The pipeline includes bispecific antibodies/T-cell engagers developed via acquisitions/collaborations.
|
$244.18B |
$101.08
+3.40%
|
|
AMGN
Amgen Inc.
Amgen leverages a bispecific antibody platform (BiTEs) in its oncology programs (e.g., BLINCYTO) and related assets.
|
$181.72B |
$333.89
-1.08%
|
|
BMY
Bristol-Myers Squibb Company
BioNTech collaboration on BNT327 represents Bispecific Antibodies as a direct modality.
|
$94.14B |
$47.91
+3.59%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
The company is advancing bispecific antibodies (e.g., Lynozyfic, Odronextamab) as a key modality.
|
$80.12B |
$763.21
+0.97%
|
|
BNTX
BioNTech SE
BNT327 is a bispecific antibody (PD-L1 x VEGF-A), a direct Bispecific Antibodies product category.
|
$22.92B |
$97.14
+1.62%
|
|
GMAB
Genmab A/S
Genmab's DuoBody bispecific antibody technology powers its bispecific therapies, aligning with Bispecific Antibodies.
|
$20.15B |
$30.84
+1.30%
|
|
INCY
Incyte Corporation
TGFßR2xPD-1 bispecific represents a distinct antibody modality in development, a separate investable category.
|
$19.93B |
$105.76
+3.63%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$12.03B |
$17.82
+10.07%
|
|
EXEL
Exelixis, Inc.
XB628 is a bispecific antibody developed by Exelixis.
|
$11.44B |
$42.41
-0.25%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.73B |
$179.60
+1.51%
|
|
MRUS
Merus N.V.
Technology platforms enable bispecific antibodies (and multispecifics), a primary Merus offering.
|
$7.24B |
$95.97
+0.21%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody aims to create conditionally-active antibodies engaging CD3, consistent with 'Bispecific Antibodies'.
|
$3.75B |
$28.89
+3.27%
|
|
IDYA
IDEAYA Biosciences, Inc.
Pipeline includes a bispecific antibody modality (e.g., IDE034) targeting two cancer-related antigens.
|
$2.98B |
$34.66
+1.99%
|
|
ZLAB
Zai Lab Limited
Bispecific antibody programs (e.g., dual-target antibodies) advancing in oncology/immunology.
|
$2.20B |
$19.93
-0.45%
|
|
IMCR
Immunocore Holdings plc
ImmTACs are bispecific TCR constructs; platform enables bispecific modalities.
|
$1.98B |
$39.24
-0.27%
|
|
ZYME
Zymeworks Inc.
Zymeworks' portfolio includes bispecific antibodies and multispecific antibody therapeutics (MSATs).
|
$1.81B |
$24.82
+3.35%
|
|
JANX
Janux Therapeutics, Inc.
Core product modality is Bispecific Antibodies engineered to engage T cells in a tumor-activated manner.
|
$1.73B |
$30.97
+7.53%
|
|
CLDX
Celldex Therapeutics, Inc.
CDX-622 is a bispecific antibody in Celldex's pipeline, aligning with Bispecific Antibodies as a core modality.
|
$1.72B |
$26.19
+1.04%
|
|
ZBIO
Zenas BioPharma, Inc.
Lead asset obexelimab is a bispecific antibody engaging two targets.
|
$1.51B |
$37.21
+3.94%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$1.13B |
$16.64
+4.85%
|
|
KOD
Kodiak Sciences Inc.
KSI-501 and KSI-101 are bispecific proteins, aligning with Bispecific Antibodies.
|
$1.10B |
$21.88
+5.34%
|
|
IMTX
Immatics N.V.
TCR Bispecifics platform (bispecific antibodies engaging tumor cells and T cells).
|
$1.05B |
$10.58
+3.73%
|
|
ABCL
AbCellera Biologics Inc.
T-cell engager / bispecific antibody programs are part of AbCellera's pipeline.
|
$1.05B |
$3.54
+1.00%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$1.05B |
$1.30
-1.52%
|
|
NKTR
Nektar Therapeutics
NKTR-0166 is a bispecific antibody program, fitting Bispecific Antibodies as an investable theme.
|
$1.03B |
$58.39
+7.57%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead candidate ficerafusp alfa is a bispecific antibody targeting two pathways, fitting Bispecific Antibodies.
|
$984.31M |
$18.85
+4.49%
|
|
MLTX
MoonLake Immunotherapeutics
SLK is a multispecific antibody/ Nanobody targeting IL-17A/F, aligning with the Bispecific Antibodies investable theme.
|
$813.80M |
$13.04
+2.88%
|
|
VIR
Vir Biotechnology, Inc.
Dual-masked bispecific antibodies (T-cell engagers) constitute a primary oncology platform.
|
$789.05M |
$6.17
+8.63%
|
|
CMPX
Compass Therapeutics, Inc.
Core asset strategy centers on Bispecific Antibodies (e.g., DLL4 x VEGF-A; PD-1 x PD-L1; PD-1 x VEGF-A).
|
$673.44M |
$4.97
+2.16%
|
|
CTMX
CytomX Therapeutics, Inc.
The PROBODY platform extends to masked T-cell engagers, aligning with Bispecific Antibodies as a modality.
|
$639.86M |
$3.96
+2.06%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$559.43M |
$12.96
+36.91%
|
|
IMAB
I-Mab
I-Mab's portfolio includes bispecific antibodies (e.g., givastomig and ragistomig), a core modality for multi-target engagement.
|
$533.68M |
$4.64
|
|
ACRS
Aclaris Therapeutics, Inc.
ATI-52.00 is a bispecific antibody, fitting the Bispecific Antibodies category.
|
$271.91M |
$2.69
+7.37%
|
|
ZURA
Zura Bio Limited
Tibulizumab is a bispecific antibody targeting IL-17A and BAFF (Bispecific Antibodies).
|
$236.02M |
$3.75
+3.44%
|
|
OABI
OmniAb, Inc.
OmniAb's platforms enable discovery of Bispecific Antibodies (OmniFlic/OmniClic), a major therapeutic modality.
|
$217.18M |
$1.78
+0.85%
|
|
CBIO
Crescent Biopharma, Inc.
CR-001 is a bispecific antibody (PD-1 x VEGF), fitting the Bispecific Antibodies investable theme.
|
$181.44M |
$14.02
+7.35%
|
|
IPHA
Innate Pharma S.A.
ANKET NK cell engagers (e.g., IPH6501) are bispecific antibody-based constructs engaging NK cells with tumor targets.
|
$147.36M |
$1.82
|
|
CGEN
Compugen Ltd.
Rilvegostomig is a PD-1/TIGIT bispecific antibody; CGEN contributes the TIGIT component, aligning with Bispecific Antibodies.
|
$136.99M |
$1.58
+3.59%
|
|
MOLN
Molecular Partners AG
Multi-target engaging modality (Switch-DARPin) aligns with bispecific antibody/category dynamics.
|
$134.10M |
$4.19
+3.71%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$97.78M |
$1.15
+5.05%
|
|
STTK
Shattuck Labs, Inc.
Pipeline includes DR3 bispecific antibodies, reflecting a major bsAb product modality.
|
$97.24M |
$2.08
+2.71%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$88.70M |
$11.90
-9.44%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$88.49M |
$1.40
|
|
ADAG
Adagene Inc.
Bispecific antibodies (e.g., ADG138 HER2xCD3 POWERbody) in the pipeline.
|
$79.69M |
$1.89
+5.00%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's CD20 x CD3 bispecific candidate demonstrates a bispecific antibody modality.
|
$76.35M |
$1.27
|
|
BCAB
BioAtla, Inc.
BA3182 is a bispecific EpCAM x CD3 T-cell engager, a bispecific antibody.
|
$51.04M |
$0.77
-11.06%
|
|
ANL
Adlai Nortye Ltd.
ANL’s AN8025 is a multi-specific antibody fusion protein, aligning with the Bispecific Antibodies category.
|
$49.77M |
$1.45
+7.41%
|
|
LVTX
LAVA Therapeutics N.V.
Gammabody antibodies are bispecific antibodies designed to engage gamma delta T cells for anti-tumor activity.
|
$45.76M |
$1.65
-5.17%
|
|
HOWL
Werewolf Therapeutics, Inc.
WTX-1011 is a T-cell engager (bispecific) targeting STEAP1, mapping to Bispecific Antibodies.
|
$39.93M |
$0.97
+11.41%
|
|
XLO
Xilio Therapeutics, Inc.
Xilio's masked T cell engager programs (ATACR/SEECR) correspond to Bispecific Antibodies.
|
$39.03M |
$0.76
+0.92%
|
|
AKTX
Akari Therapeutics, Plc
Lead to Bispecific ADC (AKTX-102) using PH1 payload, aligning with Bispecific Antibodies.
|
$22.28M |
$0.44
-1.40%
|
|
IBIO
iBio, Inc.
Pipeline includes Bispecific Antibodies such as TROP-2 x CD3 and MUC16 x CD3, reflecting a Bispecific Antibodies focus.
|
$20.64M |
$1.08
+3.33%
|
|
THAR
Tharimmune, Inc.
THAR's pipeline includes bispecific antibodies (HS1940, HS3215), aligning with Bispecific Antibodies.
|
$11.36M |
$2.50
+2.04%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Genmab collaboration targets next-generation bispecific ISACs, indicating a Bispecific Antibodies program.
|
$9.10M |
$4.85
+2.32%
|
|
INAB
IN8bio, Inc.
The INB-600 gamma-delta T cell engager platform suggests bispecific antibody-like T cell engagers.
|
$7.72M |
$1.95
+14.71%
|
|
HCWB
HCW Biologics Inc.
TRBC-derived immune cell engagers and multi-specific targeting align with Bispecific Antibodies as a modality.
|
$4.67M |
$2.20
+1.38%
|
|
APVO
Aptevo Therapeutics Inc.
APVO's lead therapies are bispecific antibodies (and trispecifics) designed to engage T cells and tumor targets using its ADAPTIR/ADAPTIR-FLEX platforms.
|
$3.72M |
$1.17
+3.10%
|
Loading company comparison...
Loading industry trends...
Loading research report...
